Dr. Russell J Schilder, MD
Claim this profileThomas Jefferson University Hospital
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
10 reported clinical trials
16 drugs studied
Area of expertise
1Ovarian Cancer
Stage IV
PD-L1 positive
Stage III
2Fallopian Tube Cancer
Stage IV
Stage III
FolRα
Affiliated Hospitals
Clinical Trials Russell J Schilder, MD is currently running
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
Abemaciclib + Olaparib
for Recurrent Ovarian Cancer
This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (recurrent platinum-resistant). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding abemaciclib to olaparib may work better to treat recurrent platinum-resistant ovarian cancer.
Recruiting1 award Phase 110 criteria
More about Russell J Schilder, MD
Clinical Trial Related2 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Russell J Schilder, MD has experience with
- Ipatasertib
- STRO-002
- ELU001
- Nivolumab
- Ipilimumab
- Abemaciclib
Breakdown of trials Russell J Schilder, MD has run
Ovarian Cancer
Fallopian Tube Cancer
Endometrial Cancer
Endometrioid Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Russell J Schilder, MD specialize in?
Russell J Schilder, MD focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are PD-L1 positive.
Is Russell J Schilder, MD currently recruiting for clinical trials?
Yes, Russell J Schilder, MD is currently recruiting for 2 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Russell J Schilder, MD has studied deeply?
Yes, Russell J Schilder, MD has studied treatments such as Ipatasertib, STRO-002, ELU001.
What is the best way to schedule an appointment with Russell J Schilder, MD?
Apply for one of the trials that Russell J Schilder, MD is conducting.
What is the office address of Russell J Schilder, MD?
The office of Russell J Schilder, MD is located at: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107 United States. This is the address for their practice at the Thomas Jefferson University Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.